Legal Action News

Your news source for lawsuits and other civil legal matters

Legal Action Recently...

April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
March 2006
February 2006
January 2006
December 2005
November 2005
October 2005
September 2005
August 2005
July 2005
June 2005
May 2005
April 2005
March 2005
February 2005
January 2005
December 2004


Legal Action News RSS Feed
RSS Feed



 

Pittsburgh Law Office Announces Class Action Suit Against Pfizer, Inc.

11 January 2005

Notice is hereby given by the Law Office of Alfred G. Yates Jr., PC that a class action lawsuit was filed in the United States District Court for the Southern District of New York on behalf of all purchasers of the common stock of Pfizer, Inc. ("Pfizer" or the "Company") (NYSE:PFE) between November 1, 2000 and December 16, 2004, inclusive, (the "Class Period").

If you wish to serve as lead plaintiff, you must move the Court no later than February 14, 2005. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff's counsel, Alfred G. Yates, Jr. at 1-800-391-5164 or via e-mail at yateslaw@aol.com. Any member of the purported class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

The complaint alleges that during the Class Period, defendants' issued false and misleading statements and omissions concerning the safety and marketability of Pfizer's Celebrex and Bextra products. At all times during the Class Period, defendants were aware that Celebrex and Bextra, drugs known as "Cox-2 inhibitors", posed serious undisclosed health risks to consumers. Defendants knew or recklessly disregarded that the undisclosed health risks posed by these drugs would limit their marketability, and that potential financial liability Pfizer faced from the harms these drugs caused posed a serious threat to the Company's financial condition. Nonetheless, defendants concealed these facts from the investing public, causing Pfizer's stock to trade at artificially inflated levels including a class period high of $48.06 per share, thereby damaging Plaintiff and the Class.

On December 17, 2004, Pfizer announced it had "received new information ... about the cardiovascular safety of its COX-2 inhibitor Celebrex (celecoxib) based on an analysis of two long-term cancer trials." On this news, Pfizer shares fell to as low as $22 per share.

Contact Law Office of Alfred G. Yates Jr., PC, Pittsburgh Alfred G. Yates, Jr., Esq., 800-391-5164 412-391-5164 412-471-1033 (facsimile) E-mail: yateslaw@aol.com

Source: PharmaLive


All trademarks and copyrighted information contained herein are the property of their respective owners.

 
Law News



A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z